When should I test a patient for Helicobacter pylori?

When to Test a Patient for H. pylori

Test all patients under 50 years old who present with dyspepsia lasting ≥4 weeks without alarm symptoms, using a non-invasive test (¹³C-urea breath test or laboratory-based monoclonal stool antigen test). 1

Age-Based Testing Strategy

Younger Patients (<45-50 years)

• Perform non-invasive H. pylori testing in patients under 45-50 years with dyspepsia who lack alarm symptoms. 2, 1 This "test-and-treat" strategy reduces unnecessary endoscopies by 62% while maintaining equivalent safety and symptom outcomes. 1
• Before testing, exclude family history of gastric cancer—this risk factor mandates specialist referral regardless of age. 2, 1
• This approach is cost-effective and captures patients with uncomplicated duodenal ulcer disease who benefit from eradication therapy. 2

Older Patients (≥45-50 years)

• Refer patients over 45-50 years with new-onset or severe dyspeptic symptoms directly to endoscopy with invasive H. pylori testing. 2, 1 The gastric cancer incidence rises markedly in this age group (19 per 100,000 men and 9 per 100,000 women in the European Community). 2
• In regions with higher gastric cancer prevalence, lower the age threshold for endoscopic referral below 45 years. 2, 1

Alarm Symptoms Requiring Immediate Endoscopy (Any Age)

Proceed directly to endoscopy—not non-invasive testing—when any of the following alarm features are present, regardless of patient age: 2, 1

• Anemia 2
• Unintentional weight loss 2
• Dysphagia (difficulty swallowing) 2
• Palpable abdominal mass 2
• Gastrointestinal bleeding 2
• Recurrent vomiting 1
• Malabsorption 2

Specific Clinical Indications for Testing

Established Indications

• Active peptic ulcer disease (gastric or duodenal ulcers) 1
• History of peptic ulcer disease, especially with complications such as bleeding 1
• Gastric MALT lymphoma 1
• Long-term PPI therapy (>1 year) due to increased risk of atrophic gastritis 1
• Atrophic gastritis or intestinal metaplasia (high-risk precancerous conditions) 1

Household and Family Testing

• Test family members living in the same household as a patient with proven active H. pylori infection to prevent transmission, reinfection, and H. pylori-related diseases. 3
• Test relatives with family history of peptic ulcer disease or gastric cancer, even if not living in the same household. 3

Preferred Testing Methods

Non-Invasive Tests (First-Line for Appropriate Patients)

• ¹³C-urea breath test (UBT): Most accurate non-invasive test with sensitivity 94.7-97% and specificity 95-97.7%. 1 Detects only active infection, not past exposure. 1
• Laboratory-based monoclonal stool antigen test: Comparable accuracy to UBT with sensitivity and specificity of approximately 93%. 1 Detects active infection rather than just antibody response. 1

Tests to Avoid

• Do not use rapid in-office serological tests—their accuracy is disappointing (sensitivity 63-97%, specificity 68-92%). 2, 1
• Do not use serology for routine diagnosis—it cannot distinguish active infection from past exposure, with overall accuracy of only 78% (range 68-82%). 1 Antibodies persist long after eradication. 1
• Serology should never be used to confirm eradication after treatment. 1

Limited Role for Serology

Validated IgG serology may be considered only in these specific circumstances: 1

• Recent antimicrobial or PPI use when medication washout is impossible
• Ulcer bleeding, atrophic gastritis, or gastric malignancies where bacterial load is low
• Large epidemiologic surveys or population screening in high-prevalence areas

Critical Medication Washout Requirements

Failure to observe medication washout periods is the leading cause of false-negative results. 1

• Stop PPIs for at least 2 weeks before performing UBT, stool antigen test, rapid urease test, histology, or culture. 1 PPIs cause 10-40% false-negative rates by suppressing bacterial load. 1
• Stop antibiotics and bismuth compounds for at least 4 weeks before testing. 1, 3
• H₂-receptor antagonists do not affect bacterial load and may be substituted when acid suppression is needed before testing. 1
• Serology is the only test unaffected by ongoing PPI therapy and can be performed without washout. 1

Common Pitfalls to Avoid

• Do not test patients currently taking PPIs unless the medication has been stopped for ≥2 weeks or serology is deliberately chosen. 1
• Do not use rapid in-office stool antigen kits—always specify a laboratory-based monoclonal assay. 1
• Do not order serology panels (IgG/IgA/IgM)—they add no diagnostic value beyond validated IgG testing. 1
• Do not test patients whose predominant presentation is typical irritable bowel syndrome rather than dyspepsia. 1
• Single antral biopsies miss 10% of infections—always obtain at least two biopsy samples from both antrum and body during endoscopy. 1

Post-Treatment Confirmation

• Test for eradication at least 4 weeks after completing therapy using UBT or laboratory-based monoclonal stool antigen test. 1
• Confirmation of eradication is strongly recommended in complicated peptic ulcer disease, gastric ulcer, and gastric MALT lymphoma. 1
• Do not use serology for post-treatment confirmation—antibodies remain elevated after H. pylori elimination. 1